logo

QLGN

Qualigen
--
--(--)
Market Open: --
--
--(--)
Post-Market: --

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About QLGN

Qualigen Therapeutics, Inc.

A biotech company that develops new therapeutic products for cancer and infectious diseases

Pharmaceutical
03/29/2004
06/24/2015
NASDAQ Stock Exchange
4
12-31
Common stock
5857 Owens Avenue, Suite 300, Carlsbad, California 92008
--
Qualigen Therapeutics, Inc., incorporated on March 29, 2004, is a Nevada limited liability company named Ritter Natural Sciences, LLC, which was converted to a Delaware corporation on September 16, 2008. The company is an early stage clinical treatment company focused on developing treatments for adult and pediatric cancers. Their business now includes an early clinical stage treatment program (QN-302) and a preclinical treatment program (Pan-RAS).

Company Financials

EPS

QLGN has released its 2023 Q3 earnings. EPS was reported at -0.64, versus the expected -0.92, beating expectations. The chart below visualizes how QLGN has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime